Soligenix Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
2analysts covering
FY EPS (est.)
-$0.40next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly6MTarget: Sufficient capital to fund operations and strategic pipeline development
Quarterly Net Loss Quarterly-2.8MTarget: Reduction in cash burn through disciplined capital management
Research and Development Expenses Quarterly1.8MTarget: Projected at $2.0 million over the next 12 months focused on Specialized BioTherapeutics
Watch Items
- Strategic Alternatives EvaluationTrigger: Execution of merger, acquisition, partnership, or asset licensing agreementAction: Re-evaluate corporate structure, pipeline focus, and long-term financial model
- SGX945 (dusquetide) Clinical Development in Behçet's DiseaseTrigger: Initiation of next-phase clinical trials or regulatory feedback from EMA/FDAAction: Assess clinical trial design, funding requirements, and commercial potential
- Cash Runway and Going Concern StatusTrigger: Cash balance falling below $3.0 million or runway dropping below 6 monthsAction: Secure non-dilutive funding, execute ATM equity sales, or implement further cost-reduction measures
Research as of 20 Jun 2026